Esketamine is a cyclohexanone derivative used for anesthesia, analgesia, and the treatment of depression for patients unresponsive to conventional antidepressants. Esketamine, also known as S(+)-ketamine, is the more active enantiomer of the ketamine racemate. The mechanism of action is not well understood, but ketamine can block Nmethyl- D-aspartate (NMDA) receptors and also interact with opioid, monoamine, adenosine, and other purinergic receptors. Esketamine has a 3- to 4-fold higher affinity for NDMA receptors than the R- enantiomer of ketamine, arketamine, and thus, results in noncompetitive binding to NMDA glutamate receptors. The antidepressant effects of esketamine is thought to be related to its anti-inflammatory effects, particularly in decreasing inducible nitric oxide synthases.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.